U.K. drugmaker McCallum gets FDA warning over data, testing issues

fda
U.K. drugmaker McCallum gets FDA warning over data, testing issues. (FDA)

McCallum, a U.K.-based drugmaker, was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

In the letter posted on the regulatory agency’s website, the FDA took McCallum to task when the company said in response to a July 2017 inspection that it was too small an enterprise and didn’t have the resources for a quality unit.

“Regardless of the size of your company, as a drug manufacturer, you must have a quality unit that is responsible for and authorized to perform certain operations,” the FDA wrote.

McCallum, an over-the-counter manufacturing operation, was found to lack testing procedures, specifications and analytical data to support the release of its products. The company also didn’t have adequate written procedures for production and process control in place, as well as failing to prepare batch production and control records.

The agency recommended the company hire a CGMP consultant to fix the issues.

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.